Metformin Superior to Glipizide in Diabetics With CADMetformin Superior to Glipizide in Diabetics With CAD

Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and arterial revascularization by 46% compared with glipizide. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news